Given that many patients are refractory or nonresponsive to conventional anticonvulsants (McTague et al., 2018; Gertler et al., 1993; Fitzgerald et al., 2019), and considering the limited success of quinidine in clinical treatment of KCNT1-related epilepsy, inhibitors targeting Slack are needed urgently (Cole et al., 2021). The gene discussed is KCNT1; the disease is epilepsy.